Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05059912 | CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma | unknown | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT03439501 | Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] | unknown | Phase 2 | 21 | Samsung Medical CenterOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05049473 |
| Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. |
| unknown |
| Phase 2 |
| 100 |
| PETHEMA FoundationOTHER |
| 1 |
| Sep 20, 2021 |
| clinicaltrials |
| NCT04736914 | Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma | unknown | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT05021770 | Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma | unknown | Phase 1 / Phase 2 | 29 | Huiqiang HuangOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT04610970 | A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL） | unknown | Phase 2 | 93 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 18, 2021 | clinicaltrials |
| NCT04994626 | Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies | unknown | Phase 2 | 20 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 6, 2021 | clinicaltrials |
| NCT00324467 | Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment(LYTPET) | unknown | Phase 2 | 150 | British Columbia Cancer AgencyOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04129710 | A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) | unknown | Phase 2 | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 16, 2021 | clinicaltrials |
| NCT04934930 | Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status(FLMRD) | unknown | Phase 2 | 40 | Meir Medical CenterOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT04917250 | GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma | unknown | Phase 2 | 15 | Beijing Tongren HospitalOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT04899414 | Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma | unknown | Phase 2 | 50 | Peking UniversityOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT04899427 | Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma | unknown | Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT04899453 | Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT04899570 | Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT04897477 | Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT03670173 | Safety and Efficacy Assessments of Osalmid in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 20 | Shanghai 10th People's HospitalOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT04891744 | Selinexor in Combination With Thalidomide and Dexamethasone in RRMM | unknown | Phase 1 / Phase 2 | 48 | Li ZhengOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT02689869 | Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma(Alternative) | unknown | Phase 2 | 98 | Ludwig-Maximilians - University of MunichOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT04860674 | A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma | unknown | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 0 | Apr 27, 2021 | clinicaltrials |
| NCT03795597 | Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)(BuMelCarAuto) | unknown | Phase 1 / Phase 2 | 36 | Loyola UniversityOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT04842487 | R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study | unknown | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 0 | Apr 13, 2021 | clinicaltrials |
| NCT02194751 | Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma | unknown | Phase 2 | 30 | XEME Biopharma Inc.INDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04831710 | Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL | unknown | Phase 2 | 83 | Sun Yat-sen UniversityOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT04827004 | A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma | unknown | Phase 2 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04705129 | Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03245905 | Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT04476459 | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL | unknown | Phase 1 / Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04796857 | Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL | unknown | Phase 1 / Phase 2 | 30 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04052659 | Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL | unknown | Phase 2 | 30 | Peking UniversityOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT03502629 | Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) | unknown | Phase 2 | 86 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT03639181 | Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226) | unknown | Phase 2 | 53 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04762745 | The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT03949062 | Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL | unknown | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT03156101 | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects | unknown | Phase 1 / Phase 2 | 24 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04431089 | Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma | unknown | Phase 2 | 122 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 28, 2021 | clinicaltrials |
| NCT04707079 | A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma | unknown | Phase 2 | 24 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04705090 | A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma | unknown | Phase 2 | 90 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jan 12, 2021 | clinicaltrials |
| NCT04676789 | Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL(SPENT) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04659434 | Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL | unknown | Phase 2 | 51 | Qian WenbinOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT04653649 | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | unknown | Phase 1 / Phase 2 | 30 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04025593 | Biomarker Guided Treatment in DLBCL | unknown | Phase 2 | 128 | Ruijin HospitalOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT04622579 | Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years(R2DLBCL80) | unknown | Phase 2 | 20 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 10, 2020 | clinicaltrials |
| NCT04615468 | A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL） | unknown | Phase 2 | 78 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 4, 2020 | clinicaltrials |
| NCT02772198 | T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies | unknown | Phase 1 / Phase 2 | 300 | Sheba Medical CenterOTHER_GOV | 1 | Nov 3, 2020 | clinicaltrials |
| NCT01965977 | Bortezomib Maintenance in High Risk DLBCL(Borma) | unknown | Phase 2 | 59 | Samsung Medical CenterOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT04600947 | Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma | unknown | Phase 2 | 69 | Taizhou HoudeAoke Biomedical Co., Ltd.INDUSTRY | 1 | Oct 23, 2020 | clinicaltrials |
| NCT02445404 | Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL | unknown | Phase 2 | 134 | Samsung Medical CenterOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02544425 | VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)(VIDL+ASCT) | unknown | Phase 2 | 27 | Samsung Medical CenterOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT03569995 | [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma | unknown | Phase 2 | 35 | Won Seog KimOTHER | 1 | Oct 22, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Sep 28, 2021source: clinicaltrials